China BioPharma Appoints Mr. Shenqian Nie, the CEO of CITIC Pharmaceutical to the Independent Board of Directors.

ISELIN, N.J. -- Techedge, Inc. (OTCBB: TEDG) announced that China BioPharma, Ltd. appointed Shenqian Nie, to the company's Board of Directors.

Peter Wang commented, "China BioPharma is pleased to announce the appointment of Mr. Shenqian Nie as a new independent member of the Board of Directors. As the current CEO of CITIC Pharmaceutical's, Mr. Nie is an experienced leader within China's pharmaceutical sector, and will prove to be a great asset in expanding China BioPharma, Ltd. business within in China and abroad".

Mr. Nie current serves as the CEO of CITIC Pharmaceuticals, which generated around $300 million in revenue last year. Mr. Nie also holds the position of Chairman for Hainan CITIC Biopharmaceutical Development Company, which is the major Influenza vaccine distributor within China. Hainan CITIC Biopharmaceutical Development was responsible for the distribution of $6 million in Influenza vaccines in China last year for Chiron Vaccines. Before entering the commercial sector, Mr. Nie held a position as an official with China's CDC (Center for Disease Control).

About China BioPharma

China BioPharma, which owns majority rights to Tianyuan Bio-pharmaceutical Co., Ltd., established in 1989, is one of China's largest non-governmental owned vaccine research manufacturers and is the first in China confirmed to GMP standard. The company's current products consist of vaccines for epidemic hemorrhagic fever (Ebola) and influenza with high reputation and market-occupying rate. The vaccines for both epidemic hemorrhagic fever and influenza virus have been awarded the National New Product Prize and National Tech Progress Prize.

Tianyuan Bio-pharmaceutical Co., Ltd. plans to establish the production of 3 to 5 new products to its research portfolio of vaccines, with 3 major in the series of aspects of bacterial, virus, and viral vaccines, having already accomplished a batch of technical achievements with autonomous intellectual property. With its recently completed production facility that is the largest and best human-vaccine production facility in China, it is also the nation's main vaccine production base whenever there is an epidemic disease outbreak in the region, such as with SARS, or Avian H5N1 Influenza (bird flu). The company currently has around 140 employees.

For more information on their current vaccines please visit www.ty-pharm.com

About Techedge Inc.

Techedge Inc. was a leading developer of mobile VoIP and wireless broadband solution provider. The Company has recently repositioned itself to focus at opportunities in the fast growing bio-pharmaceutical sector in China. For more information, please visit its website at www.techedgeinc.net

FORWARD-LOOKING STATEMENT DISCLAIMER

Some of the statements made in this press release discuss future events and developments, including our future business strategy and our ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.